Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The UDCA dosage deficit: a fate shared with CDCA.

Enrico Roda1, Stefania Liva, Francesco Ferrara

  • 1Dipartimento di Medicina Interna e Gastroenterologia, Università di Bologna, Bologna, Italy.

European Journal of Gastroenterology & Hepatology
|April 16, 2002
PubMed
Summary

Ursodeoxycholic acid (UDCA) is a key treatment for cholestatic liver diseases. Current UDCA dosages may be insufficient for primary biliary cirrhosis (PBC), necessitating a re-evaluation for optimal efficacy and long-term safety.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of a pan-ELastography Machine-learning (ELM) score to predict clinically significant portal hypertension in compensated advanced chronic liver disease.

Journal of hepatology·2026
Same author

Comparative Efficacy of Initial Treatment Strategies in Patients with Transarterial Chemoembolisation-Unsuitable Hepatocellular Carcinoma.

Liver cancer·2026
Same author

Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study.

Alimentary pharmacology & therapeutics·2026
Same author

Author's reply: Comment on "The 'ABC' of genetics in cholestatic liver diseases".

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2025
Same author

Outcome of hepatic resection for HCC in ideal and non-ideal candidates.

Hepatology communications·2025
Same author

The ``ABC'' of genetics in cholestatic liver diseases.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2025

Area of Science:

  • Hepatology
  • Pharmacology
  • Clinical Trials

Background:

  • Ursodeoxycholic acid (UDCA) is a primary treatment for cholestatic syndromes and a complementary therapy for liver diseases.
  • Limited dose-finding studies exist for UDCA, particularly concerning its efficacy and long-term safety in primary biliary cirrhosis (PBC).

Purpose of the Study:

  • To address the debate on UDCA's impact on PBC natural history by investigating optimal therapeutic dosages.
  • To evaluate the efficacy and long-term safety of UDCA therapy in patients with primary biliary cirrhosis (PBC).

Main Methods:

  • Review of existing clinical trials and literature on UDCA dosage in liver diseases, specifically PBC.
  • Analysis of current UDCA dosing regimens compared to historical dosages used for other conditions like gallstone dissolution (e.g., chenodeoxycholic acid - CDCA).

Related Experiment Videos

Main Results:

  • Evidence suggests a potential "dosage deficit" in current UDCA therapy for PBC.
  • Many clinical trials have employed conservative UDCA dosages, potentially limiting observed benefits on major endpoints.

Conclusions:

  • Re-evaluation of UDCA dosage is crucial for maximizing therapeutic effectiveness in primary biliary cirrhosis (PBC).
  • Further dose-finding studies are needed to establish optimal UDCA regimens for long-term PBC management and improved patient outcomes.